cloudsanrain
Established Member
- Reaction score
- 112
Where on the internet sells it ?
Sorry I misunderstood with 2-deoxy-D-ribose (2-desoxi-D-ribosa)Where on the internet sells it ?
All you need to do is to kill those damn demodex mites. You dont need any other treatment you loser.Sorry I misunderstood with 2-deoxy-D-ribose (2-desoxi-D-ribosa)
What about SMP?Depends on your age.
If you are over 40 then I would wait. If you are 30 then I wouldn't. You are still relatively young and could have a shot with getting intimate partners who aren't single moms. There is only a 5% chance this drug actually works. You willing to risk waiting on that for nothing?
That being said. Be sure your surgeon is really good. I went to a really good surgeon and he rejected me and said my balding was too severe for surgery. So for me, all i can do is wait for a cure before I can get this fixed and be even remotely dateable.
Still no news? About to reach 2026 and here we are
That's right, stem cells remain in the scalp even after hair loss. This makes sense because the scalp continues to regenerate, and these are the same stem cells that are already present. So we can question the benefit of adding MORE stem cells.They have shown recently that those stem cells are still there in the skin even after many years of the follicles being gone
So it works on only 31 percent of users? Talk about worthless.Definitely not Brotzu 2.0.
PP405 is developped by UCLA and the science behind it is solid. It seems the Taiwan treatment works in a similar way.
Just a quick summary:
- Mechanism: It shifts follicle metabolism from mitochondrial respiration to glycolysis, forcing stem cells to re-enter the growth phase.
- Clinical Trials: Positive Phase 2a trial results in 2024 showed 31% of men experienced >20% increased hair density.
- Usage: It is applied topically to the scalp once daily.
- Availability: Currently in development, with Phase 3 trials planned for 2026; FDA approval could potentially be as early as 2028.
So it works on only 31 percent of users? Talk about worthless.
PP405 definitely shows promise but I wouldn’t call It the “miracle hair growth treatment” it’s being marketed as online. Phase II trials are complete but phase III is where it’ll show whether or not It can compete with current FDA approved treatments. Unfortunately, It works by reactivating dormant (sleeping) follicles, so It still requires follicles to work. In other words, individuals with progressive hair loss where follicles have “died” likely won’t show any additional benefit from this than other available treatments and would still require hair transplantation for definitive treatment. Hope this helps you with future planning!
It is one of the more interesting things in the pipeline, and worth following, but I would temper the excitement with a few honest caveats.
What makes it interesting is the mechanism. Finasteride slows loss and minoxidil thickens what is already there. PP405 is trying to do something neither of those does, which is to reactivate dormant follicles and grow new hair from units that had gone quiet.
If that holds up at scale, it is a genuinely different category of treatment rather than another variation on what we already have. The caution is in the data. The figure people quote, around a third of men with heavier loss seeing a meaningful density increase, comes from a small, short trial whose main purpose was safety rather than efficacy.
Four weeks of dosing, fewer than eighty people, and the strongest result sits in a subgroup rather than across everyone. That is an encouraging early signal, not proof. Phase 3 is where a lot of promising hair compounds have quietly failed to replicate, so the real test is still ahead.
There is also the timeline. Even on the optimistic path, Phase 3 only begins this year, which means years before it could realistically be available, if it succeeds at all. And we still do not know the durability, whether results hold without continued use, or how the effect looks once it meets the real world rather than a controlled trial.
So, cautiously promising. Worth watching closely. I would not put any current plans on hold waiting for it, and I would still treat the proven options as the baseline. But of the things in development, it is one of the few aimed at a real gap rather than a marginal improvement, and that is why it is getting the attention it is.
